依达拉奉治疗血管性痴呆疗效的Meta分析

Effectiveness of Edaravone in the Treatment of Vascular Dementia:A Meta Analysis

目的：系统评价依达拉奉治疗血管性痴呆的疗效。方法：计算机检索SCI、Pub Med、EMBASE、Cochrane Library、中国生物医学文献数据库、中国知网数据库、万方数据库和维普数据库,收集所有依达拉奉对照常规治疗血管性痴呆的随机对照试验,检索时限均从建库至2014年10月25日。2位研究者独立筛选文献、提取数据、评价文献质量后,采用Rev Man 5.3软件进行Meta分析。结果：共纳入10个研究800例患者,Meta分析结果显示,依达拉奉组的MMSE评分（MD=4.38,95%CI 3.74~5.03,P〈0.00001）、总有效率（OR=4.80,95%CI 2.63~8.76,P〈0.00001）和显效率（OR=3.99,95%CI 2.28~7.01,P〈0.00001）高于对照组,差异有统计学意义。结论：目前研究结果显示,依达拉奉能促进血管性痴呆患者的神经功能恢复,可用于血管性痴呆的治疗。但由于纳入文献质量级别比较低,尚需高质量、多中心的随机对照试验进一步验证。

Objective： To systematically evaluate the effectiveness of edaravone versus conventional treatment for vascular dementia （VD）. Methods：Systematic searches were conducted in SCI, PubMed, EMBASE, Cochrane Library, CBM, CNKI, WanFang, and VIP databases, to collect all relative randomized controlled trials （RCTs） on edaravone versus conventional treating VD from inception to Oc- tober 2014. Two reviewers independently screened articles according to the inclusion and exclusion criteria, extracted data and evaluated the quality of included studies. Then statistical analysis was performed using RevMan 5.3. Results： A total of 10 RCTs involving 800 pa- tients were included. The results of meta-analysis demonstrated that compared with the conventional treatment, the edaravone group was statistical significant higher in the MMSE score（ MD = 4. 38, 95% CI 3.74 - 5.03, P 〈 0. 00001 ） , overall response rate （ OR = 4. 80, 95% CI 2. 63 - 8.76, P 〈 0. 00001 ） , the significant efficency （ OR = 3.99,95 % CI 2. 28 - 7.01, P 〈 0. 00001 ） in the treatment of VD. Conclusion： Current evidence showed that edaravone promoted recovery of neurological function in VD patients and can be used for VD treatment. However, due to lack of enough high-quality studies, more strictly-designed, multieeuter RCTs were needed in future studies.